Myriad Gets Phase IIb HIV Maturation Inhibitor From Panacos For $7M
This article was originally published in The Pink Sheet Daily
Executive Summary
Soon to split from parent Myriad Genetics, biotech obtains compound from Panacos without milestone or royalty obligations.
You may also be interested in...
Bristol Advancing Two New Mechanisms In HIV, With Focus On Treatment-Experienced Patients
An attachment inhibitor entering Phase III may offer a new option for patients who have outlived the utility of other antiretrovirals. Bristol also is advancing a second-generation maturation inhibitor of HIV into Phase IIb studies, hoping to succeed where other candidates failed to address viral mutation.
Myriad Agrees To Acquire Javelin In Stock-Swap Transaction
The Myriad Genetics spinout is hastening its progress into a commercial company by buying Javelin, although investors are grumbling about the deal terms.
Myriad Agrees To Acquire Javelin In Stock-Swap Transaction
The Myriad Genetics spinout is hastening its progress into a commercial company by buying Javelin, although investors are grumbling about the deal terms.